Literature DB >> 26034045

Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis.

Priscilla F Kerkman1, Emeline Fabre1, Ellen I H van der Voort1, Arnaud Zaldumbide2, Yoann Rombouts3, Theo Rispens4, Gertjan Wolbink4, Rob C Hoeben2, Hergen Spits5, Dominique L P Baeten6, Tom W J Huizinga1, René E M Toes1, Hans U Scherer1.   

Abstract

OBJECTIVES: Immunity to citrullinated antigens is a hallmark of rheumatoid arthritis (RA). We set out to elucidate its biology by identifying and characterising citrullinated antigen-specific B cells in peripheral blood of patients with RA.
METHODS: Differentially labelled streptavidin and extravidin tetramers were conjugated to biotinylated CCP2 or control antigens and used in flow cytometry to identify citrullinated antigen-specific B cells in peripheral blood. Tetramer-positive and tetramer-negative B cells were isolated by fluorescence activated cell sorting (FACS) followed by in vitro culture and analysis of culture supernatants for the presence of antibodies against citrullinated protein antigens (ACPA) by ELISA. Cells were phenotypically characterised by flow cytometry.
RESULTS: By combining differentially labelled CCP2 tetramers, we successfully separated citrullinated antigen-specific B cells from non-specific background signals. Isolated tetramer-positive B cells, but not tetramer-negative cells, produced large amounts of ACPA upon in vitro stimulation. Phenotypic analyses revealed that citrullinated antigen-specific B cells displayed markers of class-switched memory B cells and plasmablasts, whereas only few cells displayed a naïve phenotype. The frequency of tetramer-positive cells was high (up to 1/500 memory B cells with a median of 1/12 500 total B cells) and correlated with ACPA serum titres and spontaneous ACPA production in culture.
CONCLUSIONS: We developed a technology to identify and isolate citrullinated antigen-specific B cells from peripheral blood of patients with RA. Most cells have a memory phenotype, express IgA or IgG and are present in relatively high frequencies. These data pave the path for a direct and detailed molecular characterisation of ACPA-expressing B cells and could lead to the identification of novel therapeutic targets. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Ant-CCP; Autoimmunity; B cells; Rheumatoid Arthritis

Mesh:

Substances:

Year:  2015        PMID: 26034045     DOI: 10.1136/annrheumdis-2014-207182

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  T Cell-Dependent Affinity Maturation and Innate Immune Pathways Differentially Drive Autoreactive B Cell Responses in Rheumatoid Arthritis.

Authors:  Daniel R Lu; Andrew N McDavid; Sarah Kongpachith; Nithya Lingampalli; Jacob Glanville; Chia-Hsin Ju; Raphael Gottardo; William H Robinson
Journal:  Arthritis Rheumatol       Date:  2018-09-24       Impact factor: 10.995

2.  Beyond Autoantibodies: Biologic Roles of Human Autoreactive B Cells in Rheumatoid Arthritis Revealed by RNA-Sequencing.

Authors:  Ankit Mahendra; Xingyu Yang; Shaza Abnouf; Jay R T Adolacion; Daechan Park; Sanam Soomro; Jason Roszik; Cristian Coarfa; Gabrielle Romain; Keith Wanzeck; S Louis Bridges; Amita Aggarwal; Peng Qiu; Sandeep K Agarwal; Chandra Mohan; Navin Varadarajan
Journal:  Arthritis Rheumatol       Date:  2019-02-23       Impact factor: 10.995

Review 3.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

4.  Pathogenic Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis.

Authors:  Philip J Titcombe; Gustaf Wigerblad; Natalie Sippl; Na Zhang; Anna K Shmagel; Peter Sahlström; Yue Zhang; Laura O Barsness; Yogita Ghodke-Puranik; Azar Baharpoor; Monika Hansson; Lena Israelsson; Karl Skriner; Timothy B Niewold; Lars Klareskog; Camilla I Svensson; Khaled Amara; Vivianne Malmström; Daniel L Mueller
Journal:  Arthritis Rheumatol       Date:  2018-10-18       Impact factor: 10.995

5.  Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood.

Authors:  Marie-Claire Devilder; Mélinda Moyon; Xavier Saulquin; Laetitia Gautreau-Rolland
Journal:  J Vis Exp       Date:  2018-02-06       Impact factor: 1.355

6.  Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis.

Authors:  Kyle J Bednar; Corwin M Nycholat; Tadimeti S Rao; James C Paulson; Wai-Ping Fung-Leung; Matthew S Macauley
Journal:  ACS Chem Biol       Date:  2019-03-20       Impact factor: 5.100

7.  Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.

Authors:  Adam J Pelzek; Caroline Grönwall; Pamela Rosenthal; Jeffrey D Greenberg; Mandy McGeachy; Larry Moreland; William F C Rigby; Gregg J Silverman
Journal:  Arthritis Rheumatol       Date:  2017-05-03       Impact factor: 10.995

Review 8.  Understanding and measuring human B-cell tolerance and its breakdown in autoimmune disease.

Authors:  Kevin S Cashman; Scott A Jenks; Matthew C Woodruff; Deepak Tomar; Christopher M Tipton; Christopher D Scharer; F Eun-Hyung Lee; Jeremy M Boss; Iñaki Sanz
Journal:  Immunol Rev       Date:  2019-11-22       Impact factor: 12.988

Review 9.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

10.  Atypical phenotype and response of B cells in patients with seropositive rheumatoid arthritis.

Authors:  H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño
Journal:  Clin Exp Immunol       Date:  2021-03-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.